Biodesix (BDSX) Stock Price, News & Analysis

Company Overview

Biodesix, Inc. is a precision diagnostics company focused on developing and commercializing blood-based tests for lung cancer and other serious diseases. Headquartered in Boulder, Colorado, the company leverages proteomics, bioinformatics and machine learning to identify and validate molecular signatures that aid in diagnosis, prognosis and therapeutic selection. Since its founding in 2005, Biodesix has sought to address unmet needs in oncology by providing clinicians with noninvasive tests that complement traditional imaging and tissue biopsy methods.

The company’s portfolio includes commercially available tests such as VeriStrat®, which predicts response to certain therapies in non-small cell lung cancer, and Nodify™ Lung, designed to assess the malignancy risk of pulmonary nodules. Biodesix continues to expand its test menu through internal research and strategic collaborations, focusing on applications in immuno-oncology, targeted therapy selection and disease monitoring. In parallel, the firm invests in biomarker discovery efforts to support companion diagnostic development for pharmaceutical partners.

Biodesix operates a CLIA-certified laboratory in Boulder and serves a broad network of oncology clinics, academic medical centers and reference laboratories across the United States. The company’s tests have been incorporated into clinical workflows and guidelines, reflecting its commitment to rigorous analytical validation and clinical evidence generation. Biodesix also pursues regulatory clearances and engages with payers to facilitate reimbursement for its assays, aiming to broaden patient access and drive adoption.

Under the leadership of President and Chief Executive Officer Brian R. Nadler, Biodesix maintains a management team with deep expertise in diagnostics, life sciences and commercial strategy. The company’s board and scientific advisory committee include industry veterans and academic researchers who guide its innovation roadmap. Looking ahead, Biodesix is poised to advance its pipeline of proteomic tests and strengthen partnerships that support personalized medicine in oncology and beyond.

Key Stats

• Today's Range: $0.30 to $0.32
• 50-Day Range: $0.22 to $0.53
• 52-Week Range: $0.17 to $2.04
• Volume: 684,677 shs
• Average Volume: 2.46 million shs
• Market Capitalization: $45.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.75
• Consensus Rating: Moderate Buy

Biodesix Stock Analysis - MarketRank™

Biodesix scored higher than 67% of companies evaluated by MarketBeat, and ranked 314th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Biodesix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biodesix are expected to grow in the coming year, from ($0.35) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biodesix has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.13% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently decreased by 6.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodesix does not currently pay a dividend.

Dividend Growth

Biodesix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.13% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently decreased by 6.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $979.00 in company stock.

Percentage Held by Insiders

30.10% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.96% of the stock of Biodesix is held by institutions.

BDSX Stock Analysis - Frequently Asked Questions

How have BDSX shares performed this year?

Biodesix's stock was trading at $1.53 at the start of the year. Since then, BDSX stock has decreased by 79.6% and is now trading at $0.3120.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $17.96 million for the quarter, compared to analyst estimates of $19.50 million. Biodesix had a negative trailing twelve-month return on equity of 167.28% and a negative net margin of 54.28%.
Read the conference call transcript.

When did Biodesix IPO?

Biodesix (BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biodesix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BDSX
• CIK: 1439725
• Web: www.biodesix.com
• Phone: 303-417-0500
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biodesix: $1.75
• High Price Target: $2.00
• Low Price Target: $1.50
• Potential Upside/Downside: +495.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.93 million
• Net Margins: -54.28%
• Pretax Margin: -54.28%
• Return on Equity: -167.28%
• Return on Assets: -39.96%

Debt

• Debt-to-Equity Ratio: 3.32
• Current Ratio: 2.22
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $71.32 million
• Price / Sales: 0.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 2.10

Miscellaneous

• Outstanding Shares: 146,560,000
• Free Float: 102,448,000
• Market Cap: $43.09 million
• Optionable: Optionable
• Beta: 0.97